Filtered By:
Condition: Diabetes Type 2
Countries: Spain Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Stroke Dysbiosis Index (SDI) in Gut Microbiome Are Associated With Brain Injury and Prognosis of Stroke
Conclusions: We developed an index to measure gut microbiota dysbiosis in stroke patients; this index was significantly correlated with patients' outcome and was causally related to outcome in a mouse model of stroke. Our model facilitates the potential clinical application of gut microbiota data in stroke and adds quantitative evidence linking the gut microbiota to stroke. Introduction Ischemic stroke imposes a heavy burden on society, with 24.9 million cases worldwide (1). Although intravenous thrombolysis and endovascular treatment greatly improve some patients' prognosis, the prognosis for most pa...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Associated factors with functional prognosis of patients with acute ischemic stroke undergoing thrombectomy
CONCLUSION: Age, T2D and failed recanalization increase risk for unfavorable outcome at 90 days in patients with AIS treated with MT. Procedure time duration should be considered as a possible determinant factor in functional outcome.PMID:35042605 | DOI:10.1016/j.medcli.2021.11.010
Source: Medicina Clinica - January 19, 2022 Category: General Medicine Authors: Íñigo Rodríguez-Baz Mar ía Cristo Rodríguez-Pérez Antonio Medina Rodr íguez Ignacio Hern ández Cabezudo Yolanda Sosa Cabrera Source Type: research

Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group
Publication date: Available online 6 March 2021Source: Neurología (English Edition)Author(s): B. Fuentes, S. Amaro, M. Alonso de Leciñana, J.F. Arenillas, O. Ayo-Martín, M. Castellanos, M. Freijo, García-Pastor, M. Gomis, M. Gómez Choco, E. López-Cancio, P. Martínez Sánchez, A. Morales, E.J. Palacio-Portilla, M. Rodríguez-Yáñez, J. Roquer, T. Segura, J. Serena, J. Vivancos-Mora, A d hoc committee of the Spanish Society of Neurology’s Stroke Study Group.
Source: Neurologia - March 6, 2021 Category: Neurology Source Type: research

IJERPH, Vol. 18, Pages 3659: Sex-Related Disparities in the Incidence and Outcomes of Ischemic Stroke among Type 2 Diabetes Patients. A Matched-Pair Analysis Using the Spanish National Hospital Discharge Database for Years 2016 –2018
Conclusions: T2DM is associated with higher incidence of IS in both sexes. Men with T2DM have a higher incidence rates of IS than T2DM women. Women with T2DM have a higher risk of dying in the hospital.
Source: International Journal of Environmental Research and Public Health - April 1, 2021 Category: Environmental Health Authors: Ana L ópez-de-Andrés Rodrigo Jimenez-Garcia Valentin Hern ández-Barrera Isabel Jim énez-Trujillo Jos é J. Zamorano-León David Carabantes-Alarcon Marta Lopez-Herranz Jos é M. de Miguel-Yanes Javier de Miguel-Diez Tags: Article Source Type: research

Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
CONCLUSIONS: The prevalence of ASCVD is higher, and the involvement of the arterial territories is different in FH patients when compared with their unaffected relatives. Age, male sex, increased body mass index, hypertension, type 2 diabetes mellitus, smoking habit, and lipoprotein(a) >50 mg/dL were independently associated to ASCVD. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02693548. PMID: 27444203 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - July 20, 2016 Category: Cardiology Authors: Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P, SAFEHEART In Tags: Arterioscler Thromb Vasc Biol Source Type: research

Can This Breakfast Food Reverse Alzheimer ’ s?
I’m sure you’ve noticed how expensive eggs have gotten lately. The price has soared more than any other food in the supermarket…up 60% from one year ago.1 One reason for skyrocketing prices is the ongoing avian flu epidemic. But another reason is that demand for “nature’s perfect food” has increased substantially. And that is good news because eggs are essential for your health – including the fight against Alzheimer’s. And that means they’re worth every penny for the way they protect your brain. Two breakthrough studies back up what I’ve been telling my patients for over three decades… That ...
Source: Al Sears, MD Natural Remedies - August 25, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Brain Health Nutrition Source Type: news

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research